REPAMET 2 : Observational Study of the Switch From Metformin Monotherapy to Biotherapy With Metformin and Repaglinide
Phase of Trial: Phase IV
Latest Information Update: 04 Aug 2016
At a glance
- Drugs Metformin (Primary) ; Repaglinide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms REPAMET-2
- Sponsors Novo Nordisk
- 07 Jun 2017 Biomarkers information updated
- 01 May 2009 Actual patient number amended from 738 to 906 as reported by ClinicalTrials.gov.
- 02 Mar 2009 Additional lead trial investigator identified as reported by ClinicalTrials.gov, last updated 2-Mar-2009.